Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + fludarabine + treosulfan
- Development stage
- Unknown
- Lead developer
- University Hospital Tuebingen
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This reduced-intensity conditioning (RIC) regimen is a combination therapy evaluated by the University Hospital Tuebingen for patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT). The regimen consists of a standard backbone of fludarabine and treosulfan augmented with venetoclax, a selective B-cell lymphoma 2 (BCL-2) inhibitor. Venetoclax is added to enhance the anti-leukemic effect of the conditioning phase by inducing apoptosis in malignant cells, while fludarabine and treosulfan provide the necessary immunosuppression and myeloablation required for successful donor cell engraftment. This combination aims to reduce the risk of post-transplant relapse while maintaining a manageable safety profile compared to more intensive conditioning protocols.
- Brand names
- VenclyxtoFludaraTreocondy
- Other names
- Venetoclax-Augmented Treosulfan-Based Reduced Intensity ConditioningVenetoclax + Fludarabine + TreosulfanRIC-University Hospital Tuebingen-acute myeloid leukemia-myelodysplastic syndrome
02
Targets
BCL-2 (BCL-2 family)DNA
Beyond the preview
Go deeper on venetoclax + fludarabine + treosulfan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + fludarabine + treosulfan.